In the post hoc analysis, EGFR protein expression was evaluated in 61 patients (48.0%) from whom there were sufficient pretreatment tumor tissues for immunohistochemistry, including 32 (50%) from the RT plus icotinib group and 29 (46%) from the RT group. This evidence concerns the gene EGFR and neoplasm.